Factor VIII

Long-established role in haemophilia A and emerging evidence beyond haemostasis

Bethany Samuelson Bannow, Michael Recht, Claude Négrier, Cédric Hermans, Erik Berntorp, Hermann Eichler, Maria Elisa Mancuso, Robert Klamroth, Jamie O'Hara, Elena Santagostino, Tadashi Matsushita, Craig Kessler

Research output: Contribution to journalReview article

Abstract

Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as the standard of care for management of people with haemophilia A. It is effective for treatment of bleeding events, as prophylaxis to prevent bleeding events and preserve joint function, and to support surgery in people with haemophilia A. Despite long experience in treating haemophilia A, we are only beginning to understand the functions of FVIII beyond its established role as a coenzyme to factor IXa to expedite thrombin generation through the intrinsic pathway of coagulation. Here, we review the current role of FVIII coagulant (FVIII:C) in haemophilia A management and emerging evidence for the role of FVIII across multiple systems, including the cardiovascular system, angiogenesis and maintenance of bone health. For instance, supraphysiological FVIII levels are a risk factor for venous thromboembolism. von Willebrand factor (VWF), which forms a non-covalent complex with circulating FVIII, is an established marker and regulator of angiogenesis. In a mouse model of haemophilia, treatment with FVIII decreased expression of receptor activator of nuclear factor kappa-Β ligand (RANKL), a marker for bone turnover. Longitudinal follow-up data in people with haemophilia A are needed to confirm and extend these observations.

Original languageEnglish (US)
JournalBlood Reviews
DOIs
StatePublished - Jan 1 2019

Fingerprint

Factor VIII
Hemophilia A
Hemostasis
Proteins
Factor IXa
Hemorrhage
Coagulants
Blood Coagulation Factors
Bone Remodeling
Coenzymes
Venous Thromboembolism
von Willebrand Factor
Standard of Care
Cytoplasmic and Nuclear Receptors
Cardiovascular System
Thrombin
Joints
Maintenance
Ligands
Bone and Bones

Keywords

  • Angiogenesis
  • Bone density
  • FVIII
  • Haemophilia
  • Prophylaxis
  • Thrombin generation

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis. / Samuelson Bannow, Bethany; Recht, Michael; Négrier, Claude; Hermans, Cédric; Berntorp, Erik; Eichler, Hermann; Mancuso, Maria Elisa; Klamroth, Robert; O'Hara, Jamie; Santagostino, Elena; Matsushita, Tadashi; Kessler, Craig.

In: Blood Reviews, 01.01.2019.

Research output: Contribution to journalReview article

Samuelson Bannow, B, Recht, M, Négrier, C, Hermans, C, Berntorp, E, Eichler, H, Mancuso, ME, Klamroth, R, O'Hara, J, Santagostino, E, Matsushita, T & Kessler, C 2019, 'Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis', Blood Reviews. https://doi.org/10.1016/j.blre.2019.03.002
Samuelson Bannow, Bethany ; Recht, Michael ; Négrier, Claude ; Hermans, Cédric ; Berntorp, Erik ; Eichler, Hermann ; Mancuso, Maria Elisa ; Klamroth, Robert ; O'Hara, Jamie ; Santagostino, Elena ; Matsushita, Tadashi ; Kessler, Craig. / Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis. In: Blood Reviews. 2019.
@article{7331bf6c187445d3ba16ec8640720fa4,
title = "Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis",
abstract = "Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as the standard of care for management of people with haemophilia A. It is effective for treatment of bleeding events, as prophylaxis to prevent bleeding events and preserve joint function, and to support surgery in people with haemophilia A. Despite long experience in treating haemophilia A, we are only beginning to understand the functions of FVIII beyond its established role as a coenzyme to factor IXa to expedite thrombin generation through the intrinsic pathway of coagulation. Here, we review the current role of FVIII coagulant (FVIII:C) in haemophilia A management and emerging evidence for the role of FVIII across multiple systems, including the cardiovascular system, angiogenesis and maintenance of bone health. For instance, supraphysiological FVIII levels are a risk factor for venous thromboembolism. von Willebrand factor (VWF), which forms a non-covalent complex with circulating FVIII, is an established marker and regulator of angiogenesis. In a mouse model of haemophilia, treatment with FVIII decreased expression of receptor activator of nuclear factor kappa-Β ligand (RANKL), a marker for bone turnover. Longitudinal follow-up data in people with haemophilia A are needed to confirm and extend these observations.",
keywords = "Angiogenesis, Bone density, FVIII, Haemophilia, Prophylaxis, Thrombin generation",
author = "{Samuelson Bannow}, Bethany and Michael Recht and Claude N{\'e}grier and C{\'e}dric Hermans and Erik Berntorp and Hermann Eichler and Mancuso, {Maria Elisa} and Robert Klamroth and Jamie O'Hara and Elena Santagostino and Tadashi Matsushita and Craig Kessler",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.blre.2019.03.002",
language = "English (US)",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Factor VIII

T2 - Long-established role in haemophilia A and emerging evidence beyond haemostasis

AU - Samuelson Bannow, Bethany

AU - Recht, Michael

AU - Négrier, Claude

AU - Hermans, Cédric

AU - Berntorp, Erik

AU - Eichler, Hermann

AU - Mancuso, Maria Elisa

AU - Klamroth, Robert

AU - O'Hara, Jamie

AU - Santagostino, Elena

AU - Matsushita, Tadashi

AU - Kessler, Craig

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as the standard of care for management of people with haemophilia A. It is effective for treatment of bleeding events, as prophylaxis to prevent bleeding events and preserve joint function, and to support surgery in people with haemophilia A. Despite long experience in treating haemophilia A, we are only beginning to understand the functions of FVIII beyond its established role as a coenzyme to factor IXa to expedite thrombin generation through the intrinsic pathway of coagulation. Here, we review the current role of FVIII coagulant (FVIII:C) in haemophilia A management and emerging evidence for the role of FVIII across multiple systems, including the cardiovascular system, angiogenesis and maintenance of bone health. For instance, supraphysiological FVIII levels are a risk factor for venous thromboembolism. von Willebrand factor (VWF), which forms a non-covalent complex with circulating FVIII, is an established marker and regulator of angiogenesis. In a mouse model of haemophilia, treatment with FVIII decreased expression of receptor activator of nuclear factor kappa-Β ligand (RANKL), a marker for bone turnover. Longitudinal follow-up data in people with haemophilia A are needed to confirm and extend these observations.

AB - Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as the standard of care for management of people with haemophilia A. It is effective for treatment of bleeding events, as prophylaxis to prevent bleeding events and preserve joint function, and to support surgery in people with haemophilia A. Despite long experience in treating haemophilia A, we are only beginning to understand the functions of FVIII beyond its established role as a coenzyme to factor IXa to expedite thrombin generation through the intrinsic pathway of coagulation. Here, we review the current role of FVIII coagulant (FVIII:C) in haemophilia A management and emerging evidence for the role of FVIII across multiple systems, including the cardiovascular system, angiogenesis and maintenance of bone health. For instance, supraphysiological FVIII levels are a risk factor for venous thromboembolism. von Willebrand factor (VWF), which forms a non-covalent complex with circulating FVIII, is an established marker and regulator of angiogenesis. In a mouse model of haemophilia, treatment with FVIII decreased expression of receptor activator of nuclear factor kappa-Β ligand (RANKL), a marker for bone turnover. Longitudinal follow-up data in people with haemophilia A are needed to confirm and extend these observations.

KW - Angiogenesis

KW - Bone density

KW - FVIII

KW - Haemophilia

KW - Prophylaxis

KW - Thrombin generation

UR - http://www.scopus.com/inward/record.url?scp=85063252296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063252296&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2019.03.002

DO - 10.1016/j.blre.2019.03.002

M3 - Review article

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

ER -